You have reached the legacy site. Please visit our new site at

 Google Custom Search

(ACH-126,443, or Beta-L-Fd4C)

Also known as ACH-126443, L-Fd4C or beta-L-Fd4C, elvucitabine is a NRTI currently under investigation for the treatment of HIV infection and chronic hepatitis B.

In addition to its anti-HIV effects, elvucitabine has potent anti-HBV activity in laboratory studies. A Phase I/II study of elvucitabine in patients with chronic HBV infection demonstrated acceptable pharmacokinetics and safety. Phase II studies of elvucitabine in HBV-infected patients are underway.

Newer Anti-HIV Drugs and How to Use Them: Part I

Experimental NRTI Elvucitabine Suppresses HIV as well as Lamivudine at 48 Weeks





























































FDA-approved HIV
and AIDS Treatments
Protease Inhibitors PIs
non Nucleoside Reverse
Transcriptase Inhibitors nNRTIs
Nucleoside / Nucleotide
Reverse Transcriptase Inhibitors NRTIs
Fixed-dose Combinations
Entry / Fusion Inhibitors EIs
Integrase Inhibitors

Experimental Treatments

Articles by Topic
Adverse Events
Opportunistic Infections
Metabolic Complications
Lipodystrophy - Fat Redistribution
Treatment Guidelines